ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)

Volume 22, 38 Issues, 2015

Download PDF Flyer

Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 6th of 59 in Chemistry & Medicinal
  • 47th of 254 in Pharmacology & Pharmacy
  • 81st of 289 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.853
5 - Year: 4.115

Select Language (选择语言):

ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Current Medicinal Chemistry, 21(28): 3261-3270.

Author(s): Ivan Gentile, Federico Borgia, Antonio Riccardo Buonomo, Emanuela Zappulo, Giuseppe Castaldo and Guglielmo Borgia

Affiliation: Department of Clinical Medicine and Surgery (Ed. 18) – University of Naples “Federico II”, via S. Pansini 5, I-80131 Naples, Italy.


About 2.3% of the world’s population is infected with hepatitis C virus (HCV) and patients have a high risk of developing liver cirrhosis and its complications. Current therapeutic strategies are based on a combination of pegylatedinterferon, ribavirin and (only for patients with genotype 1 infection) a protease inhibitor (boceprevir or telaprevir). Consequently, all these combinations have the limitations of interferon. In fact, they are contraindicated in decompensated disease and in subjects with severe comorbidities, and are associated with a high rate of side effects. Moreover, they are poorly effective in advanced disease. As complete viral eradication is associated with improved disease-free survival, several molecules are under clinical development for their potential to overcome the drawbacks of currently available treatments. This review focuses on the pharmacodynamics, pharmacokinetics, safety and tolerability of ABT-450, a potent inhibitor of non-structural 3 protease. ABT-450 is a substrate of cytochrome P450; hence its co-administration with ritonavir, a cytochrome P450 inhibitor, dramatically increases the plasma concentration and half-life of ABT-450 and allows once-daily administration. Given in monotherapy for 3 days at different doses, ABT-450 causes a mean maximum viral decline of about 4 logs. Interestingly, high doses of ABT-450 are associated with a reduced and delayed development of resistance-conferring mutations. Given in combination with other direct antiviral drugs, the sustained response rate reaches 90-95% in both naïve and treatment-experienced genotype 1 patients, and tolerability is good. In conclusion, ABT-450 is an excellent component of interferon-free combinations for the treatment of chronic HCV infection.


ABT-072, ABT-267, ABT-333, ABT-450, HCV, pegylated-interferon, resistance, ribavirin, ritonavir.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 21
Issue Number: 28
First Page: 3261
Last Page: 3270
Page Count: 10
DOI: 10.2174/0929867321666140706125950

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2015 Bentham Science